Night-time symptoms: a forgotten dimension of COPD

dc.contributor.author
Agustí, Àlvar
dc.contributor.author
Hedner, J.
dc.contributor.author
Marin, J.M.
dc.contributor.author
Barbé Illa, Ferran
dc.contributor.author
Cazzola, M.
dc.contributor.author
Rennard, S.
dc.date.accessioned
2024-12-05T21:23:56Z
dc.date.available
2024-12-05T21:23:56Z
dc.date.issued
2016-03-30T08:23:44Z
dc.date.issued
2025-01-01
dc.date.issued
2011
dc.identifier
https://doi.org/10.1183/09059180.00004311
dc.identifier
0905-9180
dc.identifier
http://hdl.handle.net/10459.1/56768
dc.identifier.uri
http://hdl.handle.net/10459.1/56768
dc.description.abstract
Sleep quality is often poor in patients with chronic obstructive pulmonary disease (COPD), but these night-time symptoms are frequently unnoticed by physicians and/or not reported by patients themselves. Therefore, the prevalence and clinical impact of sleep disturbances and night-time symptoms in COPD is not well understood and has not been a clinical focus to date. To address this gap, an expert panel meeting was convened in Barcelona, Spain, in March 2011 to discuss the aetiology, evolution, burden, long-term clinical consequences and optimal management of night-time symptoms in COPD. The term ‘‘night-time symptoms’’ in COPD has not been distinctly defined in an objective sense but epidemiological data suggests that the prevalence of nocturnal symptoms and symptomatic sleep disturbance may exceed 75% in patients with COPD. The panel concluded that night-time symptoms in COPD are prevalent and bothersome; that their cause(s) are multiple and include demographic factors, such as age and obesity, pharmacotherapy, disease-specific symptoms and the presence of comorbid sleep disorders, and other medical conditions; and that potential long-term consequences can include lung function changes, increased exacerbation frequency, emergence or worsening of cardiovascular disease, cognitive effects, depression, impaired quality of life and increased mortality. To date, few interventional studies have investigated them, but emerging data suggest that bronchodilator therapy can improve them if deployed appropriately. In summary, night-time symptoms in COPD warrant further clinical investigation with validated tools.
dc.language
eng
dc.publisher
European Respiratory Society
dc.relation
Reproducció del document publicat a https://doi.org/10.1183/09059180.00004311
dc.relation
European Respiratory Review, 2011, vol. 20, núm. 1, p. 183-194
dc.rights
(c) ERS, 2011
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.subject
Burden
dc.subject
chronic bronchitis
dc.subject
emphysema
dc.subject
pharmacotherapy
dc.title
Night-time symptoms: a forgotten dimension of COPD
dc.type
article
dc.type
publishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)